AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell MobilizationBone MarrowBone Marrow TransplantationLeukapheresisBone Marrow CellsGranulocyte Colony-Stimulating FactorHematopoietic Stem CellsTransplantation, HomologousStem CellsBlood Component RemovalAntigens, CD34Transplantation ConditioningHematologic NeoplasmsGraft vs Host DiseaseMelphalanCyclophosphamideCombined Modality TherapyBone and BonesGraft SurvivalMultiple MyelomaStem Cell TransplantationBusulfanAntineoplastic Combined Chemotherapy ProtocolsBlood CellsBone Marrow DiseasesRecurrenceBlood Cell CountHematopoiesisTreatment OutcomeCord Blood Stem Cell TransplantationLymphoma, Non-HodgkinBone Marrow PurgingTissue DonorsEtoposideAntineoplastic Agents, AlkylatingMyeloablative AgonistsTransplantation ChimeraRemission InductionThiotepaWhole-Body IrradiationHistocompatibilityLeukemiaColony-Forming Units AssayFlow CytometryCell DifferentiationPlatelet CountTime FactorsHistocompatibility TestingCell SeparationDisease-Free SurvivalIfosfamideCytarabineBlood DonorsAnemia, AplasticImmunophenotypingEmbryonic Stem CellsLeukemia, Myeloid, AcuteCells, CulturedLeukocyte CountLeukocytes, MononuclearInfectionVincristineSalvage TherapyRetrospective StudiesRecombinant ProteinsTransplantation, IsogeneicAdult Stem CellsVidarabineSurvival RateBone RemodelingImmunosuppressive AgentsHodgkin DiseasePOEMS SyndromeBone Marrow ExaminationImmunomagnetic SeparationSurvival AnalysisAntigens, CDLymphomaStem Cell FactorLeukemia, Myelogenous, Chronic, BCR-ABL PositiveT-LymphocytesBone Marrow NeoplasmsCarmustineMyelodysplastic SyndromesNeoplasmsLymphocyte DepletionHematologic DiseasesGranulocytesNeoplasm, ResidualPlatelet TransfusionProchlorperazinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukocyte TransfusionDoxorubicinGranulocyte-Macrophage Colony-Stimulating FactorPluripotent Stem CellsFeasibility Studies
Multiple myelomaTransplantLymphomaDonorChemotherapyChildren with relapsedGVHDTransplantsHSCTAcquired bone marrow failure syndromesSurvivalHigh-risk or relapsedRemissionDonorsOutcomesConditioning regimensTreatment of relapsedLymphomasProgenitorsHematologicalHypocellularEngraftmentGraftTumorsNewly diagnosedMortalityLeukemicImmune systemTransplantation in patientsRisk of relapseAllogeneic stemClinicalReduced-intensityCord bloodAutologous hematopoieticProgenitor cellsCD19Acute Lymphobla2016MyeloablativePatientImmatureTissues2019CytopeniasRadioimmunotherapyMalignant
Multiple myeloma14
Transplant55
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Transplant Cell Ther. (stembook.org)
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
  • Biol Blood Marrow Transplant. (stembook.org)
  • After receiving an autologous stem cell transplant (SCT), she experienced a relapse of disease and was enrolled in an experimental protocol of immunoablative chemotherapy, followed by hematopoietic SCT at the National Institutes of Health Clinical Center in Bethesda, Maryland ( www.ClinicalTrials.gov identifier NCT00520130). (cdc.gov)
  • The bone marrow did not reconstitute, and 35 days after the initial transplant, the patient received a second SCT from the same donor after a conditioning regimen with antithymocyte globulin. (cdc.gov)
  • Microsporidium detected in clinical specimens from a stem cell transplant patient who had undergone substantial immunosuppression. (cdc.gov)
  • Data on the impact of chronic Graft-versus-host disease (cGvHD) on cognitive function (CF) and quality of life (QoL) of long-term transplant survivors are sparse. (biomedcentral.com)
  • Instruments included the Functional Assessment of Cancer Therapy-Bone marrow transplant (FACT-BMT, version 4), the FACT-Cognition Function (FACT-Cog, version 3) and the Patient Health Questionaire-4 (PHQ-4). (biomedcentral.com)
  • The study involved targeted mutational analysis of samples obtained before stem cell transplant from 1,514 MDS patients enrolled at the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. (ascopost.com)
  • To avoid relapsing and declination of the immune system, Stem Cell transplant is reported to be encouraged. (stemcelline.com)
  • The result of Stem Cell transplant shows that the success rate hits up to 60.7% while only 39.3% remain in relapsed cases. (stemcelline.com)
  • The article covers the following topic:- leukemia introduction, Stem cell transplant for treatment of Leukemia, benefits of transplant, types of transplant, complications, and how to be a stem cell donor. (stemcelline.com)
  • Topics:- Leukemia therapy with stem cell transplant, advantages of transplant, different types of transplant, side effects, and how to become a stem cell donor. (stemcelline.com)
  • The world is bestowed with a profound technique, namely, Stem Cell therapy or Stem Cell Transplant which helps in restoring your immune system and curing the disease at once. (stemcelline.com)
  • Autologous transplant - This transplant involves the extraction of stem cells from the patient's blood or bone marrow during the most stable condition of the patient. (stemcelline.com)
  • Allogeneic transplant- The transplantation involves infusing stem cells, extracted from a donor who is genetically matched with the patient. (stemcelline.com)
  • At day 100 after the transplant a sample of bone marrow is taken. (zhihuiya.com)
  • I'm on a pill form of chemo - jakafi - and beginning the stem cell therapy transplant process. (cancer.org)
  • Cuyrrently taking Jakafi to control Graft-versus-Host-Disease following an allogeneic stem cell transplant. (cancer.org)
  • Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). (mycancergenome.org)
  • Treatment for Hodgkin lymphoma (HL) is tailored to each individual and may include surgery, radiation therapy, chemotherapy, precision cancer medicines and or stem cell transplant in selected situations. (hoapb.com)
  • Bone marrow analysis at 9 months post-transplant showed normal morphologic characteristics and confirmed ongoing molecular remission. (ajmc.com)
  • This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. (ucdavis.edu)
  • This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). (ucdavis.edu)
  • Before transplant, stem cells are taken from patients and stored. (ucdavis.edu)
  • It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma. (ucdavis.edu)
  • Is radioimmunotherapy before a donor peripheral blood stem cell transplant an effective treatment for non-Hodgkin's Lymphoma? (ucdavis.edu)
  • This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. (ucdavis.edu)
  • Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. (ucdavis.edu)
  • Very few patients in this trial were treated with bone marrow transplant which had previously been the standard of care. (childrensmercy.org)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Predictors for survival after transplant relapse. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • If this happens, a peripheral stem cell transplant may be done. (epnet.com)
  • High-dose chemotherapy and stem cell transplant for testicular cancer. (epnet.com)
  • Eligibility includes having developed cytopenias (reduced blood cell counts) and not having an HLA-identical matched sibling donor for bone marrow transplant (BMT). (fanconi.org)
  • The objective of the study is to prepare the patient's body before a stem cell transplant by using an antibody-drug instead of radiation/chemotherapy to make transplants safer. (fanconi.org)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. (bioseek.eu)
  • PURPOSE: This phase II trial is studying how well giving chemotherapy with or without radiation therapy followed by donor stem cell transplant works in treating patients with hematologic cancer. (bioseek.eu)
  • The research team is working to reduce treatment toxicity and improve patient outcomes using leading-edge research to advance hematopoietic stem cell transplant methods. (lovesorghum.com)
  • After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. (biomedcentral.com)
Lymphoma30
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are not commonly used in clinical practice for treatment of B-cell lymphomas, although a subset of patients with refractory or relapsed B-cell lymphoma achieved partial or complete remissions. (bvsalud.org)
  • In this study, we tested SAHA sensitivity in 26 B-cell lymphoma cell lines and determined SAHA-interacting proteins in SAHA resistant and sensitive cell lines employing a SAHA capture compound (CC) and mass spectrometry (CCMS). (bvsalud.org)
  • In silico analysis of B-cell lymphoma samples (n = 1200) showed a wide range of FGR expression indicating that FGR expression might help to stratify patients, which clinically benefit from SAHA therapy. (bvsalud.org)
  • In conclusion, our comprehensive analysis of SAHA-interacting proteins highlights FGR as a factor involved in SAHA resistance in B-cell lymphoma. (bvsalud.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. (smw.ch)
  • I have had Peripheral T-Cell Lymphoma, Not Otherwise Specified (unknown subtype) with two relapses, Angioimmunoblastic T-Cell Lymphoma, and 20q deletion Myeodysplastic syndrome (MDS). (cancer.org)
  • 211At conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. (fredhutch.org)
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • A retrospective analysis sought to determine safety and tolerability of posttransplantation cyclophosphamide in patients with peripheral T-cell lymphoma. (hematologyadvisor.com)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • This page will give you an overview of what lymphoma is, how cells normally grow, and why lymphoma develops, symptoms of lymphoma and its treatment as well as useful links. (lymphoma.org.au)
  • Lymphoma is a type of cancer that affects your blood cells called lymphocytes. (lymphoma.org.au)
  • Because they live mostly in our lymphatic system, lymphoma often does not show up on blood tests. (lymphoma.org.au)
  • When they become cancerous lymphoma cells, you cannot fight infection as easily. (lymphoma.org.au)
  • This means you can have B-cell lymphoma or T-cell lymphoma. (lymphoma.org.au)
  • Hodgkin Lymphoma - all Hodgkin Lymphomas are lymphomas of B-cell lymphocytes. (lymphoma.org.au)
  • Hodgkin Lymphoma is identified when the cancerous B-cells develop in a certain way and become Reed-Sternberg cells - which look very different from normal B-cells. (lymphoma.org.au)
  • Non-Hodgkin Lymphoma (NHL) - these are lymphomas of all other B-cells or T-cell lymphocytes, including NK cells. (lymphoma.org.au)
  • To understand lymphoma, you first need to know a bit about how the cells in your body grow. (lymphoma.org.au)
Donor24
  • Once suitable donor organs are present, the surgeon makes an incision starting above and finishing below the sternum, cutting all the way to the bone. (wikipedia.org)
  • Most surgeons endeavour to cut blood vessels as close as possible to the heart to leave room for trimming, especially if the donor heart is of a different size than the original organ. (wikipedia.org)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • The patient received a 7/8 HLA-matched allogeneic peripheral blood SCT (with a single mismatch at the DRB1 locus) from an unrelated donor. (cdc.gov)
  • Usually, the donor may be a sibling or any blood-related person, just in case no one is available then, the nearest genetically equivalent person can also donate to the patient. (stemcelline.com)
  • Are you interested in being a stem cell donor? (stemcelline.com)
  • This lets the cells of the donor go into the bone marrow and produce normal immune cells. (zhihuiya.com)
  • This happens when the cells of the donor attacks different parts of the patient s body. (zhihuiya.com)
  • Patients who do not have a matched sibling donor but have a donor that matches in the National Marrow Donor Program. (zhihuiya.com)
  • This will further improve the chances that the patients body will accept the donor cells. (zhihuiya.com)
  • Patients will get the donor stem cells through an intravenous (IV) line that goes into a vein in their body. (zhihuiya.com)
  • Patients must have a related or unrelated peripheral blood stem cell donor as follows: 1. (mycancergenome.org)
  • The team transduced healthy volunteer donor T cells using a lentivirus to express a CAR with specificity for CD7, which is expressed in T-cell ALL. (ajmc.com)
  • Finally, patient 3 is a 15-year-old boy who first presented with mixed-phenotype acute leukemia in 2016 and underwent a first allogeneic stem cell transplantation from a matched unrelated donor. (ajmc.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • This uses healthy stem cells (immature and unformed) from the circulating blood in your body or a donor. (epnet.com)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. (bioseek.eu)
  • All patients undergo stem cell transplantation from a matched, unrelated donor on day 0. (bioseek.eu)
  • The high doses of therapy lead to destruction of patient's marrow and immune system, which is then replaced by healthy marrow from self (autologous) or donor (allogeneic) hematopoietic stem cells that have been harvested from bone marrow or peripheral blood before therapy. (lovesorghum.com)
  • The team focuses its research on donor types, treatment complications (such as graft-vs-host disease), cytomegalovirus vaccination and regimens designed to reduce the risk of relapse. (lovesorghum.com)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors. (cdc.gov)
Chemotherapy16
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Patients in this study are given a conditioning regimen of chemotherapy drugs (including fludarabine and cyclophosphamide), followed by prophylaxis against graft-versus-host disease (alemtuzumab and cyclosporine). (cdc.gov)
  • Systemic therapy is any treatment directed at destroying cancer cells throughout the body and may include chemotherapy, immunotherapy or newer precision cancer medicines. (hoapb.com)
  • Chemotherapy is any treatment involving the use of drugs to kill cancer cells. (hoapb.com)
  • Most chemotherapy drugs cannot tell the difference between a cancer cell and a healthy cell. (hoapb.com)
  • Most children with T-cell acute lymphoblastic leukemia (ALL) can be treated with standard chemotherapy regimens, but patients with induction failure or elevated minimal residual disease after consolidation generally receive allogeneic stem-cell transplantation. (ajmc.com)
  • Despite reinduction therapy and 2 blocks of high-intensity chemotherapy, he had refractory disease that manifested as persistent cytopenia with more than 80% blasts in bone marrow, all of which were expressing CD7. (ajmc.com)
  • Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. (ucdavis.edu)
  • After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. (ucdavis.edu)
  • In August of 2017, tisagenlecleucel (Kymriah) was approved for the treatment of children and adolescents with B-cell acute lymphoblastic leukemia (ALL) who have relapsed or not responded to chemotherapy. (childrensmercy.org)
  • However, relapsed ALL remains a leading cause of childhood death despite intensive cytotoxic chemotherapy often including allogeneic bone marrow transplantation. (nature.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Chemotherapy uses drugs to kill testicular cancer cells. (epnet.com)
  • The stem cells are frozen until all the cancer is killed using high-dose chemotherapy. (epnet.com)
  • This procedure starts with the patient receiving intensive chemotherapy with or without total body irradiation in an attempt to kill all cancerous cells. (lovesorghum.com)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
Children with relapsed2
  • These edited cells were investigated in 3 children with relapsed leukemia. (ajmc.com)
  • CAT CAR-T cells showed greater cytotoxicity and proliferative responses in vitro and maintained long-lived molecular remissions in children with relapsed or refractory ALL, as demonstrated in the CARPALL study 3 . (nature.com)
GVHD12
  • Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate (see Section 8). (mycancergenome.org)
  • Graft-versus-host disease ( GvHD ) is a syndrome , characterized by inflammation in different organs. (wikipedia.org)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • GvHD can also occur after a blood transfusion , known as Transfusion-associated graft-versus-host disease or TA-GvHD if the blood products used have not been gamma irradiated or treated with an approved leukocyte reduction system. (wikipedia.org)
  • Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). (unisr.it)
  • Researchers sought to determine whether vitamin D deficiency before hematopoietic stem cell transplantation would impact risk of GVHD in thalassemia major. (hematologyadvisor.com)
  • Recently, we established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse. (biomedcentral.com)
  • In this prospective trial, results indicated that low-dose PTCy is sufficient to lower acute GVHD in mouse model, partly due to the boosting of fast regulatory T cell (Treg) reconstitution. (biomedcentral.com)
  • As opposed to the aggravated circumstance in GVHD, when communication happens between enacted APC and benefactor T cells, the tissue harm brought about by myeloablative alloSCT brings about dermal enrollment of HLA class II-positive tissue fixing macrophages coinciding with expanded quantities of patient and contributor determined T cells, however without indications of explicit connection and commencement of a safe reaction. (scitechnol.com)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
Transplants3
  • There are two types of stem cell transplants, namely. (stemcelline.com)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
HSCT17
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Background: Mesenchymal stem cells (MSCs) are increasingly considered to be used as biological immunosuppressants in hematopoietic stem cell transplantation (HSCT). (uni-hannover.de)
  • In the early reconstitution phase following HSCT, natural killer (NK) cells represent the major lymphocyte population in peripheral blood and display graft-vs-leukemia (GvL) effects. (uni-hannover.de)
  • The functional interactions between NK cells and MSCs have the potential to influence the leukemia relapse rate after HSCT. (uni-hannover.de)
  • Following allogeneic hematopoietic stem cell transplantation (HSCT), interferon (IFN)-γ levels in the recipient's body can strongly influence the clinical outcome. (uni-hannover.de)
  • Total body irradiation (TBI)-based-conditioning before allogeneic hematopoietic stem cell transplantation (allo-HSCT) is standard of care in patients with acute myeloid leukemia (AML) but can cause long-term morbidity. (biomedcentral.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment modality for selected patients with acute myeloid leukemia (AML). (biomedcentral.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. (oncotarget.com)
  • We performed absolute quantification of BAALC copy numbers in peripheral blood prior (median 7 days) to HSCT in complete remission (CR) or CR with incomplete peripheral recovery in 82 acute myeloid leukemia patients using digital droplet PCR (ddPCR) technology. (oncotarget.com)
  • High pre-HSCT BAALC / ABL1 copy numbers significantly associated with higher cumulative incidence of relapse and shorter overall survival in univariable and multivariable models. (oncotarget.com)
  • Patients with high pre-HSCT BAALC / ABL1 copy numbers were more likely to experience relapse within 100 days after HSCT. (oncotarget.com)
  • Evaluation of pre-HSCT BAALC / ABL1 copy numbers in peripheral blood by ddPCR represents a feasible and rapid way to identify acute myeloid leukemia patients at high risk of early relapse after HSCT. (oncotarget.com)
  • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. (smw.ch)
  • Researchers sought to determine whether Orca-T could improve relapse and survival outcomes compared with historical controls for patients receiving allo-HSCT. (hematologyadvisor.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
Acquired bone marrow failure syndromes1
  • Genetic analysis included targeted sequencing of 129 genes selected for their known or suspected involvement in the pathogenesis of myeloid cancers or inherited or acquired bone marrow failure syndromes. (ascopost.com)
Survival8
  • Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. (stembook.org)
  • TP53 mutation was associated with poorer overall survival and increased risk of relapse. (ascopost.com)
  • among patients without TP53 mutations, survival was similar among those with therapy-related MDS vs primary MDS (HR = 1.10, P = .37). (ascopost.com)
  • PPM1D mutation vs no mutation was not associated with poorer survival in patients with therapy-related MDS without TP53 mutations (HR = 1.26, P = .39). (ascopost.com)
  • Patients who relapse after transplantation have a poor prognosis, with less than 15% long-term survival. (ajmc.com)
  • Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. (fredhutch.org)
  • Determine the relapse rate and survival rate in patients treated with this regimen. (bioseek.eu)
  • Correlate incidence and severity of graft-versus-host disease with relapse and survival in patients treated with this regimen. (bioseek.eu)
High-risk or relapsed1
  • We studied 15 consecutive patients with high-risk or relapsed CD19 + B-ALL treated with CD19 CAR-T cell therapy on the CARPALL study ( NCT02443831 ) and in whom adequate CAR-T cells could be isolated for subsequent analyses from cryopreserved samples of blood or bone marrow. (nature.com)
Remission4
  • Minimal residual disease (MRD) refers to the small number of malignant cells that remain after therapy when the patient is in remission and shows no symptoms or overt signs of disease. (smw.ch)
  • On day 27, the patient's bone marrow was hypocellular and in morphologic remission with undetectable minimal residual disease and she was discharged 52 days after stem-cell transplantation. (ajmc.com)
  • This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. (unisr.it)
  • [ 1 ] This may result in prolonged remission, but relapse is to be expected. (medscape.com)
Donors7
Outcomes5
  • Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. (stembook.org)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. (nwbio.com)
  • Physicians and scientists work side by side to set standards for stem cell transplantation and improve long-term outcomes for both pediatric and adult patients. (lovesorghum.com)
Conditioning regimens1
Treatment of relapsed1
  • This breakthrough immunotherapy has revolutionized the treatment of relapsed ALL. (childrensmercy.org)
Lymphomas6
  • Therefore, the purpose of this study was to identify molecular features that predict the response of B-cell lymphomas to SAHA treatment. (bvsalud.org)
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • Zhang QY, Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. (medscape.com)
  • Lymphomas have been called cancer of the blood, cancer of the lymphatic system and cancer of the immune system. (lymphoma.org.au)
  • Some rare lymphomas are Natural Killer cell (NK) lymphomas - NK cells are a type of T-cell lymphocyte. (lymphoma.org.au)
  • Reed-Sternberg cells are not present in Non-Hodgkin Lymphomas. (lymphoma.org.au)
Progenitors3
  • Indeed, one critical question contemplated at the Workshop was whether tumors derive from organ stem cells that retain self-renewal properties but acquire epigenetic and genetic changes required for tumorigenicity or whether tumor stem cells are proliferative progenitors that acquire self-renewal capacity. (aacrjournals.org)
  • The composition of cell types was generally more skewed to early progenitors at the point of diagnosis when compared to their matching relapse sample. (uni-heidelberg.de)
  • Drayer AL, Boer AK, Los EL, Esselink MT, Vellenga E. Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase. (rug.nl)
Hematological1
  • It is unclear whether one can generalize from two adult patients treated for CLL to other hematological malignancies and patient groups, in particular to childhood ALL, or to other CAR-T cell products. (nature.com)
Hypocellular2
  • Aplastic anemia (AA) is a hematopoietic stem cell disorder characterized by pancytopenia and hypocellular bone marrow. (haematologica.org)
  • Conditions associated with bone marrow failure such as aplastic anemia with hypocellular marrow, typical bone marrow findings of MDS are a hypercellular marrow for a persons age, dysplasia in 1 to 3 lineages manifested by pseudo Pelger-Huet nuclei, hypogranular neutrophils, micro megakaryocytes, and/or ringed sideroblasts, glass Siri glass, and increased myeloblasts in a subset of patients. (standardofcare.com)
Engraftment3
  • All patients received stem cells from bone marrow and peripheral blood, and achieved successful engraftment, except two who died before. (bvsalud.org)
  • Heredity explicit chimerism studies are regularly acquired at a few time guides after nonmyeloablative hematopoietic cell transplantation toward evaluate the rhythm and level of engraftment, and to screen join dismissal. (scitechnol.com)
  • Fragmented contributor engraftment was available just in the fringe blood T cells in a little level of patients. (scitechnol.com)
Graft13
  • Graft-versus-host disease of the gut and liver was suspected. (cdc.gov)
  • The influence of total body irradiation (TBI) as part of the conditioning regimen and chronic graft-versus-host disease (cGvHD) on cognitive function (CF) and quality of life (QoL) of very long-term survivors is still unclear. (biomedcentral.com)
  • This study will use a medicine called sirolimus instead of the usual medicine, cyclosporine, to prevent graft-versus-host disease. (zhihuiya.com)
  • The investigators then used base editing to inactivate 3 genes encoding CD52 and CD7 receptors and the b chain of the ab T-cell receptor to evade lymphodepleting serotherapy, CAR7 T-cell fratricide, and graft-versus-host disease, respectively. (ajmc.com)
  • Not to be confused with Host-versus-graft disease . (wikipedia.org)
  • Mouse colon impacted by acute graft-versus-host disease. (wikipedia.org)
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • Micrographs of grades of skin graft-versus-host disease: Ranging from grade I GvHR (with minimal vacuolization in the epidermis) to grade II GvHR (with vacuolization and dyskeratotic bodies) to grade III GvHR (with sub epidermal cleft formation) and finally to grade IV GvHR (with separation of the dermis from the epidermis). (wikipedia.org)
  • In the clinical setting, graft-versus-host disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction. (wikipedia.org)
  • In the classical sense, acute graft-versus-host disease is characterized by selective damage to the liver , skin (rash), mucosa , and the gastrointestinal tract . (wikipedia.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system , e.g., the bone marrow and the thymus ) itself, and the lungs in the form of immune-mediated pneumonitis . (wikipedia.org)
  • [6] Chronic graft-versus-host disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands . (wikipedia.org)
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
Tumors4
  • In the cancer stem cell model of tumors, there is a small subset of cancer cells, the cancer stem cells, which constitute a reservoir of self-sustaining cells with the exclusive ability to self-renew and maintain the tumor. (aacrjournals.org)
  • If cancer stem cells are relatively refractory to therapies that have been developed to eradicate the rapidly dividing cells within the tumor that constitute the majority of the nonstem cell component of tumors, then they are unlikely to be curative and relapses would be expected. (aacrjournals.org)
  • The relative abundance of different malignant cell types discovered varied amongst tumors, with some having just two identities and others having a wide range of malignant cells. (uni-heidelberg.de)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
Newly diagnosed1
  • CMH is now one of only a handful of children's hospitals treating patients on a clinical trail for newly diagnosed patients with B-cell ALL with a slower than expected response to treatment. (childrensmercy.org)
Mortality3
  • Non-relapse mortality and relapse incidence were 22.2% and 11.1%, respectively. (bvsalud.org)
  • RAS pathway mutations were associated with an increased risk of relapse with reduced-intensity conditioning, and JAK2 mutations were associated with an increased risk of nonrelapse mortality. (ascopost.com)
  • Researchers sought to determine whether greater Vδ2-positive T-cell recovery would impact mortality for patients with AML who undergo haplo-HCT. (hematologyadvisor.com)
Leukemic11
  • Patients with acute lymphoblastic leukemia (ALL) present with either symptoms relating to direct infiltration of the marrow or other organs by leukemic cells, or symptoms relating to the decreased production of normal marrow elements. (medscape.com)
  • Infiltration of the marrow by massive numbers of leukemic cells frequently manifests as bone pain. (medscape.com)
  • Signs relating to organ infiltration with leukemic cells and, to a lesser degree, lymphadenopathy may be present. (medscape.com)
  • Occasionally, patients have rashes that result from infiltration of the skin with leukemic cells. (medscape.com)
  • I could demonstrate that leukemic cells could be successfully distinguished from the microenvironment based on marker gene annotation from the human cell atlas and ploidy inference. (uni-heidelberg.de)
  • First, I characterized changes in the transcriptome and classified developmental stages of leukemic cells carrying MLL-EDC4 fusions along the hematopoietic stem cell to the myeloid trajectory compared to other MLL fusions. (uni-heidelberg.de)
  • Cell type prediction revealed extensive malignant cell diversity and a phenotype skewed towards stem- and progenitor-like populations in MLL-EDC4 leukemic cells. (uni-heidelberg.de)
  • The results agreed with differential gene expression highlighting many TFs that play a critical role in hematopoiesis, endothelial-to-hematopoietic transition, or leukemic stem cell activation. (uni-heidelberg.de)
  • Analysis from scRNA and scATAC V showed different FLT3 activity/chromatin signatures within clusters of leukemic cells in the relapse that could be explained by midostaurin resistance and the emergence of distinct subclones as detected by scDNA-seq. (uni-heidelberg.de)
  • For these patients, cellular immunotherapy could help achieve deep leukemic clearance, although chimeric antigen receptor (CAR) T-cell strategies against T-cell cancers have been difficult. (ajmc.com)
  • Although a subset of children can be cured, up to 60% of children experience further, typically fatal, disease recurrence due to non-persistence of CAR-T cells or CD19 − leukemic escape 3 , 4 . (nature.com)
Immune system9
  • These treatments require further medication to improve the immune system deteriorated during the period and sometimes even end up with destroying the healthy blood cells. (stemcelline.com)
  • ATG can exert various effects on the immune system, including T-cell depletion in the blood and peripheral tissues, down-modulation of adhesion molecules and chemokine receptors, 7 and possibly a direct effect on hematopoietic stem cells. (haematologica.org)
  • The immune system cells come from the bone marrow where they grow from special cells called stem cells. (zhihuiya.com)
  • The immune system is a network of cells, tissues, and biologic substances that defend the body against viruses, bacteria, and cancer. (hoapb.com)
  • The immune system recognizes cancer cells as foreign and can eliminate them or keep them in check-up to a point. (hoapb.com)
  • Cancer cells are very good at finding ways to avoid immune destruction, however, so the goal of immunotherapy is to help the immune system eliminate cancer cells by either activating the immune system directly or inhibiting the mechanisms of suppression of the cancer. (hoapb.com)
  • Kymriah is a novel cellular immunotherapy that reprograms a patient's own immune system to identify and kill leukemia cells. (childrensmercy.org)
  • Lymphocytes are a type of white blood cell that support our immune system by fighting infection and disease. (lymphoma.org.au)
  • Our lymphocytes are white blood cells that are a big part of our immune system. (lymphoma.org.au)
Transplantation in patients1
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
Risk of relapse1
  • 001) but not a greater risk of relapse (HR = 0.68, P = 0.26). (ascopost.com)
Allogeneic stem6
Clinical6
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • In a study reported in The New England Journal of Medicine , R. Coleman Lindsley, MD, PhD , of Dana-Farber Cancer Institute, and colleagues found that a number of mutations present in patients with myelodysplastic syndromes (MDS) were associated with poorer clinical outcome after allogeneic hematopoietic stem cell transplantation. (ascopost.com)
  • Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. (childrensmercy.org)
  • Collaborative molecular research projects will focus on the analysis of clinical biological materials collected from the study to develop an understanding of the natural history of squamous cell cancers in individuals with FA. (fanconi.org)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression. (biomedcentral.com)
Reduced-intensity2
  • Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. (stembook.org)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
Cord blood8
  • Source of stem cells were peripheral blood, bone marrow or cord blood. (biomedcentral.com)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • In the last decade, the number of transplantations of HPCs derived from cord blood has increased, particularly for children. (nationalacademies.org)
  • Since then cord blood banking programs throughout the world have expanded rapidly (Broxmeyer, 1998), with the estimated number of units stored to date exceeding 155,000 (BMDW, 2004). (nationalacademies.org)
  • Umbilical cord hematopoietic stem cell transplantation has been restricted mainly to children because there are too few stem cells in umbilical cord blood for an adult. (msdmanuals.com)
  • Because cord blood contains immature stem cells, HLA matching appears less crucial than for the other types of hematopoietic stem cell transplantation. (msdmanuals.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • For umbilical cord blood harvest, the cord is clamped after delivery of the baby, and blood is drawn from the cord with a needle and collected in a sterile bag. (msdmanuals.com)
Autologous hematopoietic3
Progenitor cells5
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • The mutation occurs in hematopoetic stem cells capable of self renewal and additional mutations are associated with clonal progression may occur in progenitor cells conferring a self renewal capability. (standardofcare.com)
  • The paradox is that the mutation provides advantage at the stem cell level and progenitor cells, with a disadvantage at the level of hematopoietic precursors. (standardofcare.com)
CD198
  • Kymriah is manufactured by harvesting the patient's own T-cells using leukapheresis and engineering these cells to attack a specific target on leukemia cells, CD19. (childrensmercy.org)
  • In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. (nature.com)
  • In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. (nature.com)
  • This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. (nature.com)
  • These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists. (nature.com)
  • B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of childhood cancer and mostly derives from immature B cells that carry the cell surface antigen CD19 (ref. 1 ). (nature.com)
  • The advent of CD19 chimeric antigen receptor (CAR)-T cell therapy in recent years has transformed the treatment of intractable ALL 2 . (nature.com)
  • An exception was long-lived CAR-T cells in two adult individuals with a different cancer-chronic lymphocytic leukemia (CLL)-in whom anti-CD19 CAR-T cells have persisted for almost a decade thus far 7 . (nature.com)
Acute Lymphobla1
  • Patient-Reported Quality of Life After Tisagenlecleucel Infusion in Children and Young Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: A Global, Single-Arm, Phase 2 Trial. (childrensmercy.org)
20162
Myeloablative2
  • Long haul resistant recuperation in more seasoned patients given hematopoietic cell transplantation after non-myeloablative molding remains ineffectively comprehended. (scitechnol.com)
  • These patients got unmanipulated, myeloablative transfers utilizing either HLA indistinguishable or HLA jumbled, related or inconsequential contributor undeveloped cells. (scitechnol.com)
Patient14
  • The patient is connected to a heart-lung machine, which circulates and oxygenates blood. (wikipedia.org)
  • The morphological examination of peripheral blood or bone marrow smears, although still an indispensable part of routine laboratory testing, is clearly insufficient for patient management, and clinicians should not ask themselves whether to look for MRD or not, but how and when. (smw.ch)
  • Patients who have a brother or sister that have stem cells that match the patient. (zhihuiya.com)
  • During these visits the patient will have a physical examination and blood tests. (zhihuiya.com)
  • One type creates a new, individualized treatment for each patient by removing some of the person's immune cells, altering them genetically to kill cancer, and then infusing them back into the bloodstream the other uses precision medications to enhance the immune systems response to the cancer. (hoapb.com)
  • Patient 1 is a 12-year-old girl with T-cell ALL with chromosomal translocation t(10;11) and deletion of chromosome 9p. (ajmc.com)
  • The patient also had cytopenia from day 0 onward and was dependent on blood and platelet support. (ajmc.com)
  • BE-CAR7 were detected in peripheral blood during a period in which the patient had very low absolute lymphocyte subset counts. (ajmc.com)
  • Patient 2 was a 13-year-old boy with a diagnosis of cortical T-cell ALL 3 years prior to study enrollment, who had relapsed while receiving maintenance treatment. (ajmc.com)
  • Once manufactured, these T-cells are returned to the patient. (childrensmercy.org)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • Patient must be willing to attend a single clinic visit lasting about 7 hours, consume one alcoholic drink, and provide saliva, mouth cells, and urine samples. (fanconi.org)
  • Patient must not be on other experimental therapies at the time and not have active cancers or concerns for high-risk bone marrow disease. (fanconi.org)
  • Hematopoietic stem cell transplantation is a procedure that involves the infusion of stem cells to treat patient malignancies or to repair diseased or defective bone marrow. (lovesorghum.com)
Immature2
  • Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. (nwbio.com)
  • MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
Tissues4
  • The source of the stem cells is either from Adult body tissues or Embryo cells. (stemcelline.com)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Examination of single T cell transcriptomes from a wide range of healthy and diseased tissues across children and adults indicated that the persistence signature may be specific to long-lived CAR-T cells. (nature.com)
  • In the present study, up-regulation of SOX9 was observed in both NPC tissues and different NPC cells. (cancerindex.org)
20191
Cytopenias2
Radioimmunotherapy2
  • A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. (fredhutch.org)
  • Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers. (fredhutch.org)
Malignant4
  • Sequencing methods that analyze the transcriptome (scRNA-seq) and epigenome (scATAC-seq) are ideally suited to resolve tumor cell heterogeneity as well as non-malignant cell types in the microenvironment. (uni-heidelberg.de)
  • A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. (curehunter.com)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • There is clonal proliferation of malignant hematopoietic stem cells, dysregulated cellular differentiation, and compromised tissue function. (standardofcare.com)